EUCTR2017-002137-32-SE
Active, not recruiting
Phase 1
Immunological responses after concomitant vaccination with the yellow fever-vaccine Stamaril and the TBE-vaccine FSME Immun, or JE-vaccine Ixiaro
Hans-Gustaf Ljunggren0 sites140 target enrollmentJuly 7, 2017
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Prevention of TBE or Japanece encephalitis by co-vaccination with the yellow fever vaccine
- Sponsor
- Hans-Gustaf Ljunggren
- Enrollment
- 140
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Individuals that need prevention of TBE, Yellow fever and JE
- •Induviduals that signed informed concent
- •Individuals between 18\-55 years of age
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 140
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Individuals that:
- •Claim that they already had vaccination, or been infected with TBE, JE or Yellow fever
- •Are allergic to eggs or something else in FSME Immun, Stamaril and Ixiaro
- •Have an autoimmune disease
- •Have difficulties donating blood
- •Take drugs against cancer
- •Take corticosteroids
- •Have a disease that had affected the brain
- •Have neurological disorders
- •Have dampened immune function or that of other reason is evaluated by the investigator as inappropriate for inclusion
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Safety and immunogenicity of concomitant vaccination with IC51 and Havrix 1440 in healthy subjects. A single-blind randomised, controlled phase 3 study.EUCTR2005-003526-25-DEIntercell AG192
Active, not recruiting
Phase 1
Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged =60 yearsVaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the new, Omicron-adapted Novavax (NVX XBB.1.5) vaccine and a 20-valent pneumococcal conjugate vaccine results in lower immunogenicity than the administration of either alone.Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2022-004118-12-ATMedical University of Vienna256
Active, not recruiting
Not Applicable
A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VACThe vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.MedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10046859Term: VaccinationEUCTR2009-011523-31-GBR & D, Cambridge University Hospitals60
Active, not recruiting
Not Applicable
Etude des réponses immunitaires après vaccination anit-influenza saisonnier et anti-H1N1 variant pandémique dans une population de personnel soignant. - FLU-HOPsymptome de la grippeMedDRA version: 12.0Level: LLTClassification code 10016797Term: Flu-like symptomsEUCTR2009-016267-11-FRInserm
Completed
Not Applicable
The efficacy of the combination of allergen vaccination and vitamin D3 in the reduction of allergen-specific nasal responses. A placebo controlled trial.RhinitisRespiratoryVasomotor and allergic rhinitisISRCTN42318360Academic Medical Centre (AMC) (Netherlands)90